Mira Pharmaceuticals Inc - Announces Positive Study Results For Ketamir-2
April 16 (Reuters) - Mira Pharmaceuticals Inc MIRA.O:
MIRA PHARMACEUTICALS INC - ANNOUNCES POSITIVE STUDY RESULTS FOR KETAMIR-2 - SEC FILING
MIRA PHARMACEUTICALS INC - KETAMIR-2 SHOWS SIGNIFICANT REDUCTION IN NEUROPATHIC PAIN SYMPTOMS - SEC FILING
MIRA PHARMACEUTICALS INC - TO INITIATE PHASE IIA TRIAL IN DIABETIC NEUROPATHY PATIENTS BY END OF 2025
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Recommended Articles
Featured Tools
Top News
SanDisk Surges 8% as Earnings Countdown Begins - Here's What Every Investor Needs to Know

Azure Growth 40%, AI Revenue 37 Billion: Why Did Microsoft Shares Fall Instead of Rise?

Nvidia Stock Prediction: Can NVDA Hit $1,000 by 2030?

Robinhood Slumps 8% After Earnings. Revenue and Profit Both Miss, Market Fears Coinbase May Follow Suit.

GOOGL Vs. MSFT: 2 Monster Stocks to Hold for the Next 5 Years

Tradingkey







